Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
斯科特·普莱沙被任命为首席执行官，Ligand Pharmicals宣布推出Pelthos Therapeutics以加速ZELSUVMI的商业化
Pharmaceutical executive Scott Plesha named CEO
制药业高管斯科特·普莱沙被任命为首席执行官
Lead product ZELSUVMI expected to be commercially available in late 2024
主要产品 ZELSUVMI 预计将于 2024 年底上市
Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
Ligand Pharmicals（纳斯达克股票代码：LGND）今天宣布成立生物制药公司Pelthos Therapeutics（Pelthos），并任命经验丰富的行业高管斯科特·普莱沙为首席执行官。
This press release features multimedia. View the full release here:
本新闻稿以多媒体为特色。在此处查看完整版本：
Scott Plesha, CEO, Pelthos Therapeutics (Photo: Business Wire)
Pelthos Therapeutics首席执行官斯科特·普莱沙（照片：美国商业资讯）
Pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of...
Pelthos 致力于将创新、安全和有效的治疗产品商业化，以帮助受疾病...
登录免费看全文
登录/注册